

Statement by Management Committee and
Audited Financial Statements

HAEMOPHILIA SOCIETY OF SINGAPORE

(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

30 JUNE 2021



HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

GENERAL INFORMATION

MANAGEMENT COMMITTEE

President	Dr. Gan Kim Loon
Vice President	Dr. Chee Chun Woei
Honorary Treasurer	Lim Keok Kung Freddy
Honorary Secretary	Wee Ai Choo Nee Lim

SECRETARY

Wee Ai Choo Nee Lim

REGISTERED OFFICE

704 Bedok Reservoir Road
#01-3622
Singapore 470704

AUDITORS

TKNP International
Public Accountants and
Chartered Accountants
Singapore

PRINCIPAL BANKERS

DBS Bank Ltd
Malayan Banking Berhad
CIMB Bank Berhad

INDEX

	<u>PAGE</u>
Statement by the Management Committee	1
Independent auditors' report	2 - 4
Statement of financial position	5
Statement of financial activities	6
Statement of changes in funds	7
Statement of cash flows	8
Notes to the financial statements	9 - 24

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

STATEMENT BY THE MANAGEMENT COMMITTEE

In the opinion of the management committee members, the financial statements of the Society are drawn up so as to give a true and fair view of the financial position of the Society as at 30 June 2021, financial performance, changes in funds and cash flows of the Society for the financial year ended on that date, and at the date of this statement, there are reasonable grounds to believe that the Society will be able to pay its debts as and when they fall due.

On behalf of the Management Committee,



Dr. Gan Kim Loon
President



Lim Keok Kung Freddy
Honorary Treasurer



Wee Ai Choo Nee Lim
Honorary Secretary

Date: 08 SEP 2021

INDEPENDENT AUDITORS' REPORT
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF HAEMOPHILIA SOCIETY OF SINGAPORE

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Haemophilia Society of Singapore ("the Society"), which comprise of statement of financial position of the Society as at 30 June 2021, the statement of financial activities, changes in funds and cash flows of the Society for the year then ended, and notes to the financial statement, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements are properly drawn up in accordance with the provisions of the Charities Act, Cap 37 and Societies Act, Cap 311 (collectively known as the "Act") and Financial Reporting Standards in Singapore (FRSs) so as to give a true and fair view of the financial position of the Society as at 30 June 2021 and of the financial performance, changes in funds and cash flows of the Society for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with Singapore Standards on Auditing (SSAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit* of the Financial Statements section of our report. We are independent of the Society in accordance with the Accounting and Corporate Regulatory Authority (ACRA), *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Management is responsible for the other information. The other information comprises the Statement by Management Committee set out on page 1.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report the fact, we have nothing to report in this regard.

Responsibilities of Management and Management Committee for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and FRSs, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

INDEPENDENT AUDITORS' REPORT
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF HAEMOPHILIA SOCIETY OF SINGAPORE (CONT'D)

Responsibilities of Management and Management Committee for the Financial Statements (Cont'd)

In preparing the financial statements, management is responsible for assessing the Society's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Society or to cease operations, or has no realistic alternative but to do so.

The management committee members' responsibilities include overseeing the Society's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material, if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Society's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Society to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with management committee members regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

INDEPENDENT AUDITORS' REPORT
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF HAEMOPHILIA SOCIETY OF SINGAPORE (CONT'D)

Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required to be kept by the Society have been properly kept in accordance with the provisions of the Act.

During the course of our audit, nothing has come to our attention that causes us to believe that during the year:

- (a) the use of donation money was not in accordance with its objectives of the Society as required under Regulation 11 of the Charities (Institutions of a Public Character) Regulations; and
- (b) the fund-raising appeals conducted by the Society during the financial year ended 30 June 2021 have not been carried out in accordance with Regulation 6 of the Societies Regulations issued under the Act and proper accounts and other records have been kept of the fundraising appeals; and
- (c) the Society has not complied with the requirements of Regulation 15 of the Charities (Institutions of a Public Character) Regulations

The engagement partner on the audit resulting in this independent auditors' report is Ong Lien Wan.


TKNP International
Public Accountants and
Chartered Accountants
Singapore



Date: 08 SEP 2021

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

STATEMENT OF FINANCIAL POSITION
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

	<u>Note</u>	<u>2021</u> S\$	<u>2020</u> S\$
ASSETS			
Non-current asset			
Property, plant and equipment	8	-	-
Current assets			
Grant receivable		100,000	-
Cash and cash equivalents	9	1,543,584	1,619,828
		<u>1,643,584</u>	<u>1,619,828</u>
Total assets		<u><u>1,643,584</u></u>	<u><u>1,619,828</u></u>
LIABILITIES AND FUNDS			
LIABILITIES			
Current liabilities			
Sundry payables	10	7,584	5,784
FUNDS			
Unrestricted funds			
Accumulated fund		1,465,735	1,543,779
Haemophilia Welfare fund	11	50,265	50,265
Dulcie Wilson Scholarship fund	12	20,000	20,000
		<u>1,536,000</u>	<u>1,614,044</u>
Restricted funds			
Sym Asia Singapore fund	13	100,000	-
		<u>100,000</u>	<u>-</u>
Total liabilities and funds		<u><u>1,643,584</u></u>	<u><u>1,619,828</u></u>

See accompanying notes to the financial statements.

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

	<u>Note</u>	<u>2021</u> S\$	<u>2020</u> S\$
<u>Income</u>			
Income from generated funds			
Voluntary income	4	175,489	306,178
Activities for generating funds		8,208	17,576
Investment income	5	13,945	25,281
Income from charitable activities		<u>4,480</u>	<u>38,949</u>
Total income		<u>202,122</u>	<u>387,984</u>
<u>Expenditures</u>			
Cost of generating funds	6	7,623	24,444
Charitable activities	7	265,589	256,179
Government cost		6,800	6,800
Finance cost		<u>154</u>	<u>1,356</u>
Total expenditures		<u>(280,166)</u>	<u>(288,779)</u>
(Deficit)/Surplus before tax		(78,044)	99,205
Income tax expense	14	<u>-</u>	<u>-</u>
(Deficit)/Surplus for the year, representing total comprehensive (loss)/income for the year		<u>(78,044)</u>	<u>99,205</u>

See accompanying notes to the financial statements.

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

STATEMENT OF CHANGES IN FUNDS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

	Unrestricted funds			Restricted funds	
	Accumulated fund	Haemophilia Welfare fund	Dulcie Wilson Scholarship fund	Sym Asia Singapore Fund	Total
	S\$	S\$	S\$	S\$	S\$
At 1 July 2019	1,444,574	50,265	20,000	-	1,514,839
Surplus for the year, representing total comprehensive income for the year	99,205	-	-	-	99,205
At 30 June 2020	<u>1,543,779</u>	<u>50,265</u>	<u>20,000</u>	<u>-</u>	<u>1,614,044</u>
At 1 July 2020	1,543,779	50,265	20,000	-	1,614,044
(Deficit) for the year, representing total comprehensive (loss) for the year	(78,044)	-	-	-	(78,044)
Funding received	-	-	-	100,000	100,000
At 30 June 2021	<u>1,465,735</u>	<u>50,265</u>	<u>20,000</u>	<u>100,000</u>	<u>1,636,000</u>

See accompanying notes to the financial statements.

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

	<u>Note</u>	<u>2021</u> S\$	<u>2020</u> S\$
Cash flows from operating activities			
(Deficit)/Surplus before tax		(78,044)	99,205
Adjustment for:			
Fixed deposit interest	5	<u>(13,945)</u>	<u>(25,281)</u>
Operating (deficit)/surplus before working capital changes		(91,989)	73,924
Changes in working capital:			
(Increase) in grant receivable		(100,000)	-
Increase/(Decrease) in sundry payables		<u>1,800</u>	<u>(1,236)</u>
Net cash flows (used in)/generated from operating activities		<u>(190,189)</u>	<u>72,688</u>
Cash flows from investing activities			
Fixed deposit interest	5	13,945	25,281
Decrease/(Increase) in fixed deposit		<u>200,116</u>	<u>(71,205)</u>
Net cash flows generated from/(used in) investing activities		<u>214,061</u>	<u>(45,924)</u>
Cash flows from financing activities			
Increase in funding		<u>100,000</u>	-
Net cash flows generated from/(used in) financing activities		<u>100,000</u>	-
Net increase in cash and cash equivalents		123,872	26,764
Cash and cash equivalents at beginning of financial year		54,355	27,591
Cash and cash equivalents at end of financial year	9	<u><u>178,227</u></u>	<u><u>54,355</u></u>

See accompanying notes to the financial statements

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1. GENERAL INFORMATION

Haemophilia Society of Singapore (the "Society") is domiciled and registered in Singapore with the Registrar of Societies under the Societies Act, Chapter 311. The Society is a charity registered under the Commissioner of Charities, the Charities Act, Chapter 37. The registered office is at 704 Bedok Reservoir Road #01-3622, Singapore 470704.

The objects of the Society are to look after the welfare of people with haemophilia and their families through giving help and support.

The Society is being accorded Institution of a Public Character ("IPC") status for the period from 1 January 2020 to 31 December 2021.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1) BASIS OF PREPARATION

The financial statements of the Society have been drawn up in accordance with Singapore Financial Reporting Standards ("FRS") and operating risks and practices of the Ministry of Health's Health Endowment Fund Scheme. They are also subject to the provision of the Charities Act, Cap 311.

The financial statements are presented in Singapore dollar ("S\$"), which is also the functional currency of the Society.

The financial statements have been prepared in accordance with the historical cost convention except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with FRS requires management to exercise its judgement in the process of applying the Society's accounting policies. It also requires the use of certain critical accounting estimates and assumptions. Areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 3 to the financial statements.

During the financial year, the Society has adopted the new and revised FRS that are relevant and mandatory for the current financial year. The adoption of these FRS did not result in any significant changes in the accounting policies.

2.2) ADOPTION OF NEW AND AMENDED STANDARDS AND INTERPRETATIONS

The accounting policies adopted are consistent with those of the previous financial year except that in current financial year, the Society has adopted all the new and amended standards which are relevant to the Society and are effective as per the dates stated in the FRS. The adoption of these standards did not have any material effect on the financial performance or position of the Society.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.3) PROPERTY, PLANT AND EQUIPMENT

All items of property, plant and equipment are initially recorded at cost. Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. The cost of property, plant and equipment includes its purchase price and any costs directly attribute to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property, plant and equipment if the obligation for dismantlement, removal or restoration is included as a consequence of acquiring or using the property, plant and equipment.

Depreciation is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful lives are as follows:

	<i>Useful life</i>
Equipment	5 years

The useful lives, residual values and depreciation method are reviewed at the end of each reporting period, and adjusted prospectively, if appropriate.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on de - recognition of the asset is included in profit or loss in the year the asset is derecognised.

2.4) IMPAIRMENT OF NON - FINANCIAL ASSETS

The Society assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when an annual impairment testing for an asset is required, the Society makes an estimate of the asset's recoverable amount.

An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs of disposal and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

Impairment losses are recognised in profit or loss

A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case, the carrying amount of the asset is increased to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised previously. Such reversal is recognised in profit or loss.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.5) FINANCIAL ASSETS

Initial recognition and measurement

Financial assets are recognised when, and only when the entity becomes a party to the contractual provisions of the financial instruments.

At initial recognition, the Society measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Subsequent measurement

Investments in debt instruments

Subsequent measurement of debt instruments depends on the Society's business model for managing the asset and the contractual cash flow characteristics of the asset. The three measurement categories for classification of debt instruments are amortised cost, fair value through other comprehensive income (FVOCI) and FVPL. The Society only has debt instruments at amortised cost.

Financial assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in profit or loss when the assets are derecognised or impaired, and through the amortisation process.

Derecognition

A financial asset is derecognised where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or loss that had been recognised in other comprehensive income for debt instruments is recognised in profit or loss.

2.6) IMPAIRMENT OF FINANCIAL ASSETS

The Society recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Society expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is recognised for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.7) CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise fixed deposits and cash at bank that are subjected to an insignificant risk of changes in value.

2.8) FINANCIAL LIABILITIES

Initial recognition and measurement

Financial liabilities are recognised when, and only when, the Society becomes a party to the contractual provisions of the financial instrument. The Society determines the classification of its financial liabilities at initial recognition.

All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable transaction costs.

Subsequent measurement

After initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are derecognised, and through the amortisation process.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. On derecognition, the difference between the carrying amounts and the consideration paid is recognised in profit or loss.

2.9) FUNDS

The funds of a Society comprise unrestricted income funds and restricted funds/special trust.

Unrestricted funds are expendable at the discretion of the governing board members in furtherance of the Society's objectives. If part of an unrestricted fund is earmarked for a particular project, it may be designated as a separate fund, but the designation has an administrative purpose only, and does not legally restrict the governing board members' discretion to apply the fund. Some governing board members have power to declare specific trusts over unrestricted funds. If such a power is available and is exercised, the assets affected will form a restricted fund, and the governing board members' discretion to apply the fund will be legally restricted. Unrestricted funds can be spent on the same purposes as restricted funds, for example, by spending more on a project for which a restricted grant has provided funding. Therefore, unrestricted funds may be transferred to meet any shortfall in a restricted fund.

A power of accumulation as stipulated explicitly in the governing instruments will allow governing board members to create or augment endowment funds (restricted capital funds) from income funds (restricted or unrestricted). Without this power, governing board members may not create endowment from income funds. Governing board members need to be aware that if they use income funds to erect, extend or improve a building on land that is a permanent endowment asset, then those income funds shall be treated as permanent endowment.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.9) FUNDS (CONT'D)

The governing board members may earmark part of the Society's unrestricted funds to be used for particular purposes in the future. Such sums are described as "designated funds" and shall be accounted for as part of the Society's unrestricted funds. The governing board members have the power to re-designate such funds with unrestricted funds. When a designation has been made at the reporting date, the amount of the designation may be adjusted subsequent to the period end if more accurate information becomes available.

2.10) REVENUE RECOGNITION

Income is recognised in the statement of financial activities when the effect of a transaction or other event results in an increase in the Society's net assets.

The following factors must also be met before income is recognised:

- Entitlement - the Society has control over the rights or other access to the resource, enabling the Society to determine its future application;
- Certainty - it is probable that the income will be received; and
- Measurement - the amount of the income can be measured by the Society with sufficient reliability.

The following specific recognition criteria must also be met before income is recognised:

Donations

Donations are recognised when received. Income recognition is only deferred when the donor specifies that the donations can only be used in future accounting periods or the donor has imposed certain conditions that must be met before the Society has unconditional entitlement.

Grants

Grants are not recognised until there is reasonable assurance that the grant will be received and all conditions attached to it have been met.

Membership subscription

Membership subscription is recognised on accrual basis.

Interest income

Interest income from bank deposits is accrued on a time apportion basis using effective interest method.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.11) EXPENDITURES

Expenditure is recognised in the statement of financial activities once the goods or services have been received unless the expenditure qualifies for capitalisation as non-current assets. Expenditure on performance-related grants is recognised to the extent the specified service or goods have been provided. Expenditures in the statement of financial activities are classified under the cost of generating funds, cost of charitable activities and governance cost.

Cost of generating funds

The costs of generating funds are those costs attributable to generating income for the Society, which includes direct attributable overheads.

Cost of charitable activities

All resources applied in undertaking activities to meet the Society's charitable objectives are classified under cost of charitable activities. The primary charitable activities are to assist with treatment cost to haemophilia members by providing subsidies for treatment costs at three local government hospitals. Additionally, the Society initiated Merit Award Programme to encourage young members in school to excel in their studies. These awards are in monetary terms, ranging from S\$200 to S\$600 depending on their education levels.

Government cost

Governance costs are those incurred in compliance with constitutional and statutory requirement including external audit and other related professional fees.

2.12) RELATED PARTY

A related party is a person or entity that is related to the Society and includes:

- (a) A person or a close member of that person's family which is related to the Society if that person:
 - (i) Has control or joint control over the Society;
 - (ii) Has significant influence over the Society; or
 - (iii) Is a member of the key management personnel of the Society or of parent of the Society.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

2.12) RELATED PARTY (CONT'D)

- (b) An entity which is related to the Society if any of the following conditions applies:
- (i) The entity and the Society are members of the same Society (which means that each parent, subsidiary and fellow subsidiary is related to the others).
 - (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a Society of which the other entity is a member).
 - (iii) Both entities are joint ventures of the same third party.
 - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third party.
 - (v) The entity is a post-employment benefit plan for the benefit of employees of either the Society or an entity related to the Society. If the Society is itself such a plan, the sponsoring employers are also related to the Society.
 - (vi) The entity is controlled or jointly controlled by a person identified (a).
 - (vii) A person identified in (a) (i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
 - (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity.

The following are not necessarily related parties:

- (a) Two entities simply because they have a director or other member of key management personnel in common.
- (b) Two ventures simply because they share joint control over a joint venture.

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Society.

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect reported amounts of income, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

3.1) JUDGEMENTS MADE IN APPLYING ACCOUNTING POLICIES

The management is of the opinion that there are no significant judgements (other than those involving estimates) that have a significant effect on the amounts recognised in the financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (CONT'D)

3.2) KEY SOURCES OF ESTIMATION UNCERTAINTY

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting period are discussed below. The Society based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Society. Such changes are reflected in the assumptions when they occur.

COVID-19

The outbreak of COVID-19 pandemic globally and in Singapore is causing significant disturbance and slowdown of economic activity. The Society has considered internal and external information while finalising various estimates in relation to its financial statements up to the date of approval of the financial statements by the Management Committee and has not identified any material impact on the carrying value of assets, liabilities or provisions. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration. The Society is monitoring the situation closely and shall take actions as appropriate based on any material changes to future economic conditions.

4. VOLUNTARY INCOME

	<u>2021</u> S\$	<u>2020</u> S\$
Donations	<u>175,489</u>	<u>306,178</u>

During the financial year, the Society issued tax exempt receipts for donation collected amounting to S\$170,132 (2020: S\$295,148).

5. INVESTMENT INCOME

	<u>2021</u> S\$	<u>2020</u> S\$
Fixed deposit interest	<u>13,945</u>	<u>25,281</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

6. COST OF GENERATING FUNDS

	<u>2021</u> S\$	<u>2020</u> S\$
Charity event	4,440	20,598
IT related cost	293	190
Entertainment and refreshment	159	841
Miscellaneous expenses	-	122
Postage and stationery	2,731	2,693
	<u>7,623</u>	<u>24,444</u>

7. CHARITABLE ACTIVITIES

	<u>2021</u> S\$	<u>2020</u> S\$
Membership fee – National Council of Social Service	54	54
Membership fee – World Federation of Haemophilia	358	383
Cost of treatment subsidised under three local hospitals:		
- National University Hospital	73,894	79,951
- Singapore General Hospital	102,044	60,306
- KK Women's and Children's Hospital	86,639	112,017
Members' welfare activities	2,600	3,468
	<u>265,589</u>	<u>256,179</u>

8. PROPERTY, PLANT AND EQUIPMENT

	Equipment S\$	Total S\$
<u>Cost</u>		
At 1 July 2019	599	599
Additions	-	-
At 30 June 2020	<u>599</u>	<u>599</u>
Additions	-	-
At 30 June 2021	<u>599</u>	<u>599</u>
<u>Accumulated depreciation</u>		
At 1 July 2019	599	599
Depreciation	-	-
At 30 June 2020	<u>599</u>	<u>599</u>
Depreciation	-	-
At 30 June 2021	<u>599</u>	<u>599</u>
<u>Carrying amount</u>		
At 30 June 2020	<u>-</u>	<u>-</u>
At 30 June 2021	<u>-</u>	<u>-</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

9. CASH AND CASH EQUIVALENTS

	<u>2021</u> S\$	<u>2020</u> S\$
Cash at bank	178,227	54,355
Fixed deposits	1,365,357	1,565,473
	<u>1,543,584</u>	<u>1,619,828</u>

Fixed deposits are placed at the tenure of 12 months (2020: 12 to 24 months) and earned interest ranging from 0.45% to 1.90% (2020: 1.45% to 1.90%) per annum.

Cash and cash equivalents are denominated in Singapore dollar.

For the purpose of presenting the statement of cash flows, the cash and cash equivalents comprise the followings:

	<u>2021</u> S\$	<u>2020</u> S\$
Cash and cash equivalents (as above)	1,543,584	1,619,828
Less: Fixed deposits	(1,365,357)	(1,565,473)
	<u>178,227</u>	<u>54,355</u>

10. SUNDRY PAYABLES

	<u>2021</u> S\$	<u>2020</u> S\$
Accruals	3,054	3,054
Subscription received in advance	4,530	2,730
	<u>7,584</u>	<u>5,784</u>

Sundry payables are denominated in Singapore dollar.

11. HAEMOPHILIA WELFARE FUND

	<u>2021</u> S\$	<u>2020</u> S\$
Balance at beginning and end of the year	<u>50,265</u>	<u>50,265</u>

The welfare fund was established from the receipt of an initial donation amounting to \$25,000 from the National Council of Social Service in 1990. This fund is used to assist haemophilia members facing financial difficulties. Financial assistance ranges from S\$25 to S\$2,500 and are reviewed and approved on quarterly basis where financial conditions warrant.

All financial assistance provided by subsidising proportion of treatment costs were expended under accumulated fund. The Haemophilia Welfare fund was kept for emergency use.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

12. DULCIE WILSON SCHOLARSHIP FUND

	<u>2021</u> S\$	<u>2020</u> S\$
Balance at beginning and end of the year	<u>20,000</u>	<u>20,000</u>

The scholarship fund was established in memory of Mrs. Dulcie Wilson back in 2010. The sum of S\$20,000 would be used to assist haemophilia members who pursue their studies in a recognised local university. No application was received as at reporting date.

13. SYM ASIA SINGAPORE FUND

	<u>2021</u> S\$	<u>2020</u> S\$
Balance at beginning and end of the year	-	-
Funding received	<u>100,000</u>	-
Balance at beginning and end of the year	<u>100,000</u>	<u>-</u>

The Sym Asia Singapore fund is a restricted fund granted for the purpose of supporting treatment subsidies for members. The grant period is for 1 July 2021 to 30 June 2023. It will be disbursed in 4 tranches. The amount disbursed is for the projected shortfall for the financial period ended 30 June 2021. Any unutilised amount shall be rolled over to support the same purpose in the subsequent years.

14. INCOME TAX EXPENSE

The Society is an approved charitable organisation under the Charities Act, Cap. 37 and an Institute of a Public Character under the Income Tax Act, Cap. 134. Therefore, the Society is exempted from income tax under section 13(1) (ZM) of the Income Tax Act. No provision of income tax payable is made in the financial statements.

15. RELATED PARTY TRANSACTIONS

A related party includes the management committee members and key management of the Society. It also includes an entity or person that directly or indirectly controls, is controlled by, or is under common or joint control with these persons. It also includes members of the key management personnel or close members of the family of any individual referred to herein and others, who have the ability to control, jointly control or significantly influence by or for which significant voting power in such entity resides with, directly or indirectly, any such individual. Key management personnel include the president and the direct reporting senior officers.

The management committee members, or people connected with them, have not received remuneration, or other benefits, from the Society for which they are responsible, or from institutions connected with the Society.

There is no claim by the management committee members for services provided to the Society, either by reimbursement to the management committee members or by providing the management committee members with an allowance or by direct payment to third party.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

15. RELATED PARTY TRANSACTIONS (CONT'D)

Conflict of interest

All management committee members, sub-committees and staff members of the Society are required to read and understand the conflict of interest policy in place and make full disclosure of interests, relationships and not declaring that could potentially result in conflict of interest. When a conflict of situation arises, the member or staff shall abstain from participating in the discussion, decision-making and voting on the matters.

16. FINANCIAL RISK MANAGEMENT

Risk management is integral to the whole business of the Society. The Society has a system of controls in place to create an acceptable balance between the cost of risks occurring and the cost of managing the risk. The management continually monitors the Society's risk management process to ensure that an appropriate balance between risk and control is achieved. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Society's activities.

The Society's activities expose it to a variety of financial risks from its operations. The key financial risk include credit risk, and liquidity risk.

Credit risk

Credit risk refers to the risk that the counterparty will default on its contractual obligations resulting in a loss to the Society. The Society's exposure to credit risk arises primarily from cash and cash equivalents, the Society minimises credit risk by dealing exclusively with high credit rating counterparties.

The Society has adopted a policy of only dealing with creditworthy counterparties. The Society performs ongoing credit evaluation of its counterparties' financial condition and generally do not require a collateral.

The Society considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period.

The Society has determined the default event on a financial asset to be when internal and/or external information indicates that the financial asset is unlikely to be received.

Cash and cash equivalents are also subject to the impairment requirements of the standard on financial instruments. There was no identified impairment loss.

Liquidity risk

Liquidity risk refers to the risk that the Society will encounter difficulties in meeting its short-term obligations due to shortage of funds. The Society's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. It is managed by matching the payment and receipt cycles. The Society finances its working capital requirements through funds generated from operations.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

16. FINANCIAL RISK MANAGEMENT (CONT'D)

Liquidity risk (Cont'd)

Analysis of financial instruments by remaining contractual maturities

The table below summarises the maturity profile of the Society's financial assets and liabilities at the reporting date based on contractual undiscounted repayment obligations.

	<u>Carrying amount</u> S\$	<u>Total</u> S\$	<u>Within 1 year</u> S\$
2021			
<u>Financial assets</u>			
Grant receivable	100,000	100,000	100,000
Cash and cash equivalents	1,543,584	1,543,584	1,543,584
Total undiscounted financial assets	<u>1,643,584</u>	<u>1,643,584</u>	<u>1,643,584</u>
<u>Financial liabilities</u>			
Sundry payables	7,584	7,584	7,584
Total undiscounted financial liabilities	<u>(7,584)</u>	<u>(7,584)</u>	<u>(7,584)</u>
Total net undiscounted financial assets	<u>1,636,000</u>	<u>1,636,000</u>	<u>1,636,000</u>
2020			
<u>Financial assets</u>			
Cash and cash equivalents	1,619,828	1,619,828	1,619,828
Total undiscounted financial assets	<u>1,619,828</u>	<u>1,619,828</u>	<u>1,619,828</u>
<u>Financial liabilities</u>			
Sundry payables	5,784	5,784	5,784
Total undiscounted financial liabilities	<u>(5,784)</u>	<u>(5,784)</u>	<u>(5,784)</u>
Total net undiscounted financial assets	<u>1,614,044</u>	<u>1,614,044</u>	<u>1,614,044</u>

17. FAIR VALUE OF FINANCIAL INSTRUMENTS

(a) Fair value hierarchy

The Society categorises fair value measurements using a fair value hierarchy that is dependent on the valuation inputs used as follows:

- Level 1 – Quoted price (unadjusted) in active markets for identical assets or liabilities that the Society can access at the measurement date,
- Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, and
- Level 3 – Unobservable inputs for the asset or liability.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

17. FAIR VALUE OF FINANCIAL INSTRUMENTS (CONT'D)

Fair value measurements that use inputs of different hierarchy levels are categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

(b) Assets and liabilities not measured at fair value

Cash and cash equivalents, grant receivables and sundry payables

The carrying amounts approximate their fair values due to the short-term nature of these balances.

18. FINANCIAL INSTRUMENTS BY CATEGORY

At the reporting date, the aggregate carrying amounts of financial assets at amortised cost and financial liabilities at amortised cost were as follows:

Financial assets measured at amortised cost

	<u>2021</u> S\$	<u>2020</u> S\$
Grant receivables	100,000	-
Cash and cash equivalents	1,543,584	1,619,828
	<u>1,643,584</u>	<u>1,619,828</u>

Financial liabilities measured at amortised cost

	<u>2021</u> S\$	<u>2020</u> S\$
Sundry payables	7,584	5,784

19. RESERVES POLICY

The primary objective of the reserve policy is to ensure that the Society maintains a healthy and strong financial position for its continuous growth. The ratio below excludes cost of generating funds to indicate how well the Society performed in serving its objective while leaving the activity for raising funds aside.

The Society regards the Haemophilia Welfare, Dulcie Wilson Scholarship and Sym Asia Singapore funds as funds for emergency use only and expends all its fundraising and charitable activities mainly from the accumulated fund. The ratio of reserves to annual operating expenditures indicates a decrease of 1.80% due to a decrease in accumulated fund as compared to the last financial year.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

19. RESERVES POLICY (CONT'D)

	<u>2021</u> S\$	<u>2020</u> S\$	% increase/ (decrease)
<u>Unrestricted funds:</u>			
Accumulated fund	1,465,735	1,543,779	(5.06)
Haemophilia Welfare fund	50,265	50,265	-
Dulcie Wilson Scholarship fund	20,000	20,000	-
	<u>1,536,000</u>	<u>1,614,044</u>	
<u>Restricted funds:</u>			
Sym Asia Singapore fund	100,000	-	100
	<u>100,000</u>	<u>-</u>	
<u>Operating expenditures:</u>			
Charitable activities	265,589	256,179	3.67
Governance cost	6,800	6,800	-
Finance cost	154	1,356	(88.6)
	<u>272,543</u>	<u>264,335</u>	
Ratio of reserves to annual operating expenditures	<u>6.00</u>	<u>6.11</u>	(1.80)

The financial position of the Society will be reviewed and monitored by management committee members on a monthly basis to ensure sufficient funds for its continuous operation.

20. NEW OR REVISED ACCOUNTING STANDARDS AND INTERPRETATIONS NOT YET EFFECTIVE

The Society has not adopted the following standards applicable to the Society that have been issued but not yet effective:

Description	Effective for annual periods beginning on or after
Amendment to FRS 116 <i>Leases: Covid-19-Related Rent Concessions</i>	1 June 2020
Amendments to FRS 109 <i>Financial Instruments</i> , FRS 39 <i>Financial Instruments: Recognition and Measurement</i> , FRS 107 <i>Financial Instruments: Disclosures</i> , FRS 104 <i>Insurance Contracts</i> , FRS 116 <i>Leases: Interest Rate Benchmark Reform – Phase 2</i>	1 January 2021
Amendments to FRS 16 <i>Property, Plant and Equipment: Proceeds before Intended Use</i>	1 January 2022
Amendments to FRS 37 <i>Provisions, Contingent Liabilities and Contingent Assets: Onerous Contracts – Cost of Fulfilling a Contract</i>	1 January 2022
Annual Improvements to FRSs 2018-2020	1 January 2022
Amendments to FRS 1 <i>Presentation of Financial Statements: Classification of Liabilities as Current or Non-current</i>	1 January 2023
Amendments to FRS 110 <i>Consolidated Financial Statements and FRS 28 Investments in Associates and Joint Ventures: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Date to be determined

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

The management committee members expect that the adoption of the standards above will have no material impact on the financial statements in the year of initial application.

21. AUTHORISATION OF FINANCIAL STATEMENTS FOR ISSUE

The financial statements of the Society and for the year ended 30 June 2021 were authorised for issue in accordance with a resolution of the management committee members as at the date of the Statement by the Management Committee.

THE FOLLOWING SCHEDULES DO NOT FORM PART OF THE STATUTORY FINANCIAL STATEMENTS

HAEMOPHILIA SOCIETY OF SINGAPORE
(Charity Registration No.: 00374)
(Society Registration No.: S85SS0047A)

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021

	<u>2021</u> S\$	<u>2020</u> S\$
Income		
Income from generated funds		
Voluntary income:		
Donations	175,489	306,178
Activities for generating funds:		
Project calendar	8,208	8,455
Project Apatite	-	9,121
Other collections / receipts	-	-
	8,208	17,576
Investment income:		
Fixed deposit interest	13,945	25,281
Income from charitable activities		
Charity events collection	-	11,930
Charity movie premier	-	22,909
Members' subscriptions	4,480	4,110
	4,480	38,949
Total income	<u>202,122</u>	<u>387,984</u>
Expenditures		
Cost of generating funds		
Charity event	4,440	20,598
IT related costs	293	190
Entertainment and refreshment	159	841
Miscellaneous expenses	-	122
Postage and stationery	2,731	2,693
	7,623	24,444
Charitable activities		
Membership fee - National Council of Social Service	54	54
Membership fee - World Federation of Haemophilia	358	383
Cost of treatment subsidised under three local hospitals:		
- National University Hospital	73,894	79,951
- Singapore General Hospital	102,044	60,306
- KK Women's and Children's Hospital	86,639	112,017
Members' welfare activities	2,600	3,468
	265,589	256,179
Governance cost		
Auditors' remuneration	3,000	3,000
Accountancy fees	3,800	3,800
	6,800	6,800
Finance cost		
Bank charges	154	1,356
Total expenditures	<u>(280,166)</u>	<u>(288,779)</u>
(Deficit)/Surplus before tax	<u>(78,044)</u>	<u>99,205</u>

This statement is for management information only and does not form part of the financial statements.